 |
9 Products |  |
120 Diseases | | 9 Products |
|
46 Trials |  |
2133 News |  |
| «12...1617181920212223242526...2930» |
- spanlecortemlocel (MGTA-456) / Magenta Therap
[VIRTUAL] HIGH DOSE STEM CELL THERAPIES, LIKE MGTA-456, ENABLE COMPLETE NEURAL AND PERIPHERAL DISEASE CROSS-CORRECTION THROUGH RAPID AND ROBUST HEMATOPOIETIC ENGRAFTMENT (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3695;
We show that high dose HSCT leads to rapid and durable improved disease correction, including normalization of behavioral outcomes, via robust microglial engraftment. High dose cell therapies, like MGTA-456, may resolve neurologic disease in patients with IMDs and other neurodegenerative diseases caused by defective microglia.
- Ovastat (treosulfan) / Medac, fludarabine IV / Generic mfg.
[VIRTUAL] TREOSULFAN COMBINED WITH FLUDARABINE AS CONDITIONING REGIMEN IN ALLOGENEIC STEM CELL TRANSPLANATION OF MYELOID DISEASES, ALLOWS HIGH OVERALL SURVIVAL WITH LOW RELATED TOXICITY (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3616;
The replacement of Busulfan by Treosulfan in the conditioning regimen of these patients may result in a lower toxicity, especially in patients with high comorbidity index (HCTI). Treo-FLU conditioning is effective in patients with a high risk of relapse including recurrence after previous transplantation, with a low MRT rate despite high HCT-CI, especially in patients with MDS.
- Ovastat (treosulfan) / Medac, fludarabine IV / Generic mfg.
[VIRTUAL] TREOSULFAN COMBINED WITH FLUDARABINE AS CONDITIONING REGIMEN IN ALLOGENEIC STEM CELL TRANSPLANATION OF MYELOID DISEASES, ALLOWS HIGH OVERALL SURVIVAL WITH LOW RELATED TOXICITY (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3615;
The replacement of Busulfan by Treosulfan in the conditioning regimen of these patients may result in a lower toxicity, especially in patients with high comorbidity index (HCTI). Treo-FLU conditioning is effective in patients with a high risk of relapse including recurrence after previous transplantation, with a low MRT rate despite high HCT-CI, especially in patients with MDS.
- Ovastat (treosulfan) / Medac, fludarabine IV / Generic mfg.
[VIRTUAL] TREOSULFAN COMBINED WITH FLUDARABINE AS CONDITIONING REGIMEN IN ALLOGENEIC STEM CELL TRANSPLANATION OF MYELOID DISEASES, ALLOWS HIGH OVERALL SURVIVAL WITH LOW RELATED TOXICITY (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3614;
The replacement of Busulfan by Treosulfan in the conditioning regimen of these patients may result in a lower toxicity, especially in patients with high comorbidity index (HCTI). Treo-FLU conditioning is effective in patients with a high risk of relapse including recurrence after previous transplantation, with a low MRT rate despite high HCT-CI, especially in patients with MDS.
- Campath (alemtuzumab) / Sanofi
[VIRTUAL] UK EXPERIENCE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR ACTIVATING PI3K MUTATIONS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3496;
All received serotherapy (Alemtuzumab=10, ATG= 4)... HSCT is a curative treatment for patients with activating PI3K mutation but almost a third of patients developed GF requiring an additional procedure.
- Campath (alemtuzumab) / Sanofi
[VIRTUAL] UK EXPERIENCE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR ACTIVATING PI3K MUTATIONS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3495;
All received serotherapy (Alemtuzumab=10, ATG= 4)... HSCT is a curative treatment for patients with activating PI3K mutation but almost a third of patients developed GF requiring an additional procedure.
- Campath (alemtuzumab) / Sanofi
[VIRTUAL] UK EXPERIENCE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR ACTIVATING PI3K MUTATIONS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3494;
All received serotherapy (Alemtuzumab=10, ATG= 4)... HSCT is a curative treatment for patients with activating PI3K mutation but almost a third of patients developed GF requiring an additional procedure.
- tacrolimus / Generic mfg., sirolimus / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] CALCINEURIN-INHIBITORS OR SIROLIMUS PTCY-MMF BASED GVHD PROPHYLAXIS: COMPARATIVE STUDY IN 132 PTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3307;
The association of both calcineurin-inhibitors or sirolimus to PTCy and MMF gives similar results in terms of aGvHD and cGvHD incidence after unmanipulated haplo-SCT. Patients receiving calcineurin-inhibitor-based GvHD prophylaxis showed higher incidence of endothelial complications.
- tacrolimus / Generic mfg., sirolimus / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] CALCINEURIN-INHIBITORS OR SIROLIMUS PTCY-MMF BASED GVHD PROPHYLAXIS: COMPARATIVE STUDY IN 132 PTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3306;
The association of both calcineurin-inhibitors or sirolimus to PTCy and MMF gives similar results in terms of aGvHD and cGvHD incidence after unmanipulated haplo-SCT. Patients receiving calcineurin-inhibitor-based GvHD prophylaxis showed higher incidence of endothelial complications.
- tacrolimus / Generic mfg., sirolimus / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] CALCINEURIN-INHIBITORS OR SIROLIMUS PTCY-MMF BASED GVHD PROPHYLAXIS: COMPARATIVE STUDY IN 132 PTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3305;
The association of both calcineurin-inhibitors or sirolimus to PTCy and MMF gives similar results in terms of aGvHD and cGvHD incidence after unmanipulated haplo-SCT. Patients receiving calcineurin-inhibitor-based GvHD prophylaxis showed higher incidence of endothelial complications.
- Kyprolis (carfilzomib) / Amgen, Ono Pharma, methotrexate / Generic mfg., cyclosporine / Generic mfg.
[VIRTUAL] CARFILZOMIB IN ADDITION TO STANDARD CYCLOSPORINE/ METHOTREXATE COMBINATION EFFECTIVELY PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FROM UNRELATED DONORS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3283;
Carfilzomib in addition to standard cyclosporine/ methotrexate is safe and allows better prevention of acute GVHD without compromising the graft-versus-leukemia effect, resulting in favorable outcome after unrelated-donor transplant. Larger randomized prospective studies are required to confirm these initial promising results.
- Kyprolis (carfilzomib) / Amgen, Ono Pharma, methotrexate / Generic mfg., cyclosporine / Generic mfg.
[VIRTUAL] CARFILZOMIB IN ADDITION TO STANDARD CYCLOSPORINE/ METHOTREXATE COMBINATION EFFECTIVELY PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FROM UNRELATED DONORS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3282;
Carfilzomib in addition to standard cyclosporine/ methotrexate is safe and allows better prevention of acute GVHD without compromising the graft-versus-leukemia effect, resulting in favorable outcome after unrelated-donor transplant. Larger randomized prospective studies are required to confirm these initial promising results.
- Kyprolis (carfilzomib) / Amgen, Ono Pharma, methotrexate / Generic mfg., cyclosporine / Generic mfg.
[VIRTUAL] CARFILZOMIB IN ADDITION TO STANDARD CYCLOSPORINE/ METHOTREXATE COMBINATION EFFECTIVELY PREVENTS ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FROM UNRELATED DONORS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3281;
Carfilzomib in addition to standard cyclosporine/ methotrexate is safe and allows better prevention of acute GVHD without compromising the graft-versus-leukemia effect, resulting in favorable outcome after unrelated-donor transplant. Larger randomized prospective studies are required to confirm these initial promising results.
- sirolimus / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] ALLOGENEIC PERIPHERAL BLOOD TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SIROLIMUS FROM HAPLOIDENTICAL AND MATCHED DONORS: 'SIR-PTCY' RESULTS IN 249 PATIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3184;
This strategy provide low mortality and superimposable severe GVHD in patients presenting a low-intermediate DRI, translating in a relevant long-term survival. Clinical Trial Registry: NA
- sirolimus / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] ALLOGENEIC PERIPHERAL BLOOD TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SIROLIMUS FROM HAPLOIDENTICAL AND MATCHED DONORS: 'SIR-PTCY' RESULTS IN 249 PATIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3183;
This strategy provide low mortality and superimposable severe GVHD in patients presenting a low-intermediate DRI, translating in a relevant long-term survival. Clinical Trial Registry: NA
- sirolimus / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] ALLOGENEIC PERIPHERAL BLOOD TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AND SIROLIMUS FROM HAPLOIDENTICAL AND MATCHED DONORS: 'SIR-PTCY' RESULTS IN 249 PATIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3182;
This strategy provide low mortality and superimposable severe GVHD in patients presenting a low-intermediate DRI, translating in a relevant long-term survival. Clinical Trial Registry: NA
- Ovastat (treosulfan) / Medac, busulfan / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] CONDITIONING REGIMEN WITH FLUDARABIN/TREOSULFAN COMPARED TO BUSULFAN/CYCLOPHOSPHAMID PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION IN YOUNGER PATIENTS WITH AML AND MDS: A SINGLE CENTER RETROSPECTIVE ANALYSIS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3109;
The tendency to a more favorable overall survival within the Bu/Cy group might partially be explained by the higher rate of active disease and older patients within the Flu/Treo group. Therefore the comparison of the Flu/Treo conditioning regimen with MAC should be studied in a randomized, prospective trial.
- Ovastat (treosulfan) / Medac, busulfan / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] CONDITIONING REGIMEN WITH FLUDARABIN/TREOSULFAN COMPARED TO BUSULFAN/CYCLOPHOSPHAMID PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION IN YOUNGER PATIENTS WITH AML AND MDS: A SINGLE CENTER RETROSPECTIVE ANALYSIS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3108;
The tendency to a more favorable overall survival within the Bu/Cy group might partially be explained by the higher rate of active disease and older patients within the Flu/Treo group. Therefore the comparison of the Flu/Treo conditioning regimen with MAC should be studied in a randomized, prospective trial.
- Ovastat (treosulfan) / Medac, busulfan / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] CONDITIONING REGIMEN WITH FLUDARABIN/TREOSULFAN COMPARED TO BUSULFAN/CYCLOPHOSPHAMID PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION IN YOUNGER PATIENTS WITH AML AND MDS: A SINGLE CENTER RETROSPECTIVE ANALYSIS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3107;
The tendency to a more favorable overall survival within the Bu/Cy group might partially be explained by the higher rate of active disease and older patients within the Flu/Treo group. Therefore the comparison of the Flu/Treo conditioning regimen with MAC should be studied in a randomized, prospective trial.
- Ovastat (treosulfan) / Medac, melphalan / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] SEQUENTIAL HLA—HAPLOIDENTICAL TRANSPLANTATION USING PTCY IN HIGH-RISK MDS/AML OF THE ELDERLY: A MATCHED-PAIR ANALYSIS OF TWO DIFFERENT REGIMENS USING TREOSULFAN OR MELPHALAN FOR RIC (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3076;
We suggest that treosulfan-based RIC in haplo-HSCT might be an alternative in elderly pts with low leukemic burden. However, its intensity should be reconsidered
- Ovastat (treosulfan) / Medac, melphalan / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] SEQUENTIAL HLA—HAPLOIDENTICAL TRANSPLANTATION USING PTCY IN HIGH-RISK MDS/AML OF THE ELDERLY: A MATCHED-PAIR ANALYSIS OF TWO DIFFERENT REGIMENS USING TREOSULFAN OR MELPHALAN FOR RIC (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3075;
We suggest that treosulfan-based RIC in haplo-HSCT might be an alternative in elderly pts with low leukemic burden. However, its intensity should be reconsidered
- Ovastat (treosulfan) / Medac, melphalan / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] SEQUENTIAL HLA—HAPLOIDENTICAL TRANSPLANTATION USING PTCY IN HIGH-RISK MDS/AML OF THE ELDERLY: A MATCHED-PAIR ANALYSIS OF TWO DIFFERENT REGIMENS USING TREOSULFAN OR MELPHALAN FOR RIC (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3074;
We suggest that treosulfan-based RIC in haplo-HSCT might be an alternative in elderly pts with low leukemic burden. However, its intensity should be reconsidered
- Campath (alemtuzumab) / Sanofi
[VIRTUAL] IRRADIATION-FREE RE-CONDITIONING FOR T-CELL DEPLETED HAPLO-IDENTICAL STEM CELL TRANSPLANTATION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3070;
Omitting irradiation spares side effects and reduces the infection risk. With all patients showing a robust engraftment and only few complications post-transplantation, this conditioning seems to be a promising regimen, notwithstanding the relatively small cohort size of 9 patients.
- Campath (alemtuzumab) / Sanofi
[VIRTUAL] IRRADIATION-FREE RE-CONDITIONING FOR T-CELL DEPLETED HAPLO-IDENTICAL STEM CELL TRANSPLANTATION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3069;
Omitting irradiation spares side effects and reduces the infection risk. With all patients showing a robust engraftment and only few complications post-transplantation, this conditioning seems to be a promising regimen, notwithstanding the relatively small cohort size of 9 patients.
- Campath (alemtuzumab) / Sanofi
[VIRTUAL] IRRADIATION-FREE RE-CONDITIONING FOR T-CELL DEPLETED HAPLO-IDENTICAL STEM CELL TRANSPLANTATION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3068;
Omitting irradiation spares side effects and reduces the infection risk. With all patients showing a robust engraftment and only few complications post-transplantation, this conditioning seems to be a promising regimen, notwithstanding the relatively small cohort size of 9 patients.
- Ovastat (treosulfan) / Medac, cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] TREOSULFAN-BASED CONDITIONING IN PAEDIATRIC T-CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTS: A SINGLE CENTRE EXPERIENCE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3034;
Either Fludarabine-Melphalan or Fludarabine-Cyclophosphamide was used in combination with Treosulfan. Treosulfan-based conditioning is a well-tolerated and effective regimen for paediatric TCD haplo-PBSC transplants.
- Ovastat (treosulfan) / Medac, cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] TREOSULFAN-BASED CONDITIONING IN PAEDIATRIC T-CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTS: A SINGLE CENTRE EXPERIENCE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3033;
Either Fludarabine-Melphalan or Fludarabine-Cyclophosphamide was used in combination with Treosulfan. Treosulfan-based conditioning is a well-tolerated and effective regimen for paediatric TCD haplo-PBSC transplants.
- Ovastat (treosulfan) / Medac, cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] TREOSULFAN-BASED CONDITIONING IN PAEDIATRIC T-CELL DEPLETED HAPLOIDENTICAL STEM CELL TRANSPLANTS: A SINGLE CENTRE EXPERIENCE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3032;
Either Fludarabine-Melphalan or Fludarabine-Cyclophosphamide was used in combination with Treosulfan. Treosulfan-based conditioning is a well-tolerated and effective regimen for paediatric TCD haplo-PBSC transplants.
- Ovastat (treosulfan) / Medac, busulfan / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] CONDITIONING REGIMENS IN AML: MYELOABLATIVE TREOSULFAN-BASED REGIMEN VS. CYCLOPHOSPHAMIDE/TOTAL BODY IRRADIATION AND BUSULFAN-CYCLOPHOSPHAMIDE CONDITIONING REGIMENS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3007;
Our results suggest non-inferiority of the Treo14 conditioning to CyTBI or BuCy regimens in AML patients ≥45 years old. NRM did not differ between the groups.
- Ovastat (treosulfan) / Medac, busulfan / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] CONDITIONING REGIMENS IN AML: MYELOABLATIVE TREOSULFAN-BASED REGIMEN VS. CYCLOPHOSPHAMIDE/TOTAL BODY IRRADIATION AND BUSULFAN-CYCLOPHOSPHAMIDE CONDITIONING REGIMENS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3006;
Our results suggest non-inferiority of the Treo14 conditioning to CyTBI or BuCy regimens in AML patients ≥45 years old. NRM did not differ between the groups.
- Ovastat (treosulfan) / Medac, busulfan / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] CONDITIONING REGIMENS IN AML: MYELOABLATIVE TREOSULFAN-BASED REGIMEN VS. CYCLOPHOSPHAMIDE/TOTAL BODY IRRADIATION AND BUSULFAN-CYCLOPHOSPHAMIDE CONDITIONING REGIMENS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_3005;
Our results suggest non-inferiority of the Treo14 conditioning to CyTBI or BuCy regimens in AML patients ≥45 years old. NRM did not differ between the groups.
- Ovastat (treosulfan) / Medac, mycophenolate mofetil / Generic mfg., cyclosporine / Generic mfg.
[VIRTUAL] SEQUENTIAL CONDITIONING: FLAMSA-TBI VERSUS FLAMSA-TREO IN HIGH RISK ACUTE MYELOID LEUKEMIA (AML) IN FIRST COMPLETE REMISSION AND HIGH RISK MYELODYSPLASTIC SYNDROME (MDS) (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2992;
The reduced toxicity profile of Treosulfan could favor especially AML patients in first complete remission. A larger prospective series of patients is needed in order to confirm these promising preliminary findings.
- Ovastat (treosulfan) / Medac, mycophenolate mofetil / Generic mfg., cyclosporine / Generic mfg.
[VIRTUAL] SEQUENTIAL CONDITIONING: FLAMSA-TBI VERSUS FLAMSA-TREO IN HIGH RISK ACUTE MYELOID LEUKEMIA (AML) IN FIRST COMPLETE REMISSION AND HIGH RISK MYELODYSPLASTIC SYNDROME (MDS) (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2991;
The reduced toxicity profile of Treosulfan could favor especially AML patients in first complete remission. A larger prospective series of patients is needed in order to confirm these promising preliminary findings.
- Ovastat (treosulfan) / Medac, mycophenolate mofetil / Generic mfg., cyclosporine / Generic mfg.
[VIRTUAL] SEQUENTIAL CONDITIONING: FLAMSA-TBI VERSUS FLAMSA-TREO IN HIGH RISK ACUTE MYELOID LEUKEMIA (AML) IN FIRST COMPLETE REMISSION AND HIGH RISK MYELODYSPLASTIC SYNDROME (MDS) (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2990;
The reduced toxicity profile of Treosulfan could favor especially AML patients in first complete remission. A larger prospective series of patients is needed in order to confirm these promising preliminary findings.
- Ovastat (treosulfan) / Medac, sirolimus / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS ≥ 65 YEARS WITH HEMATOLOGICAL MALIGNANCIES AFTER MYELOABLATIVE TREOSULFAN-BASED CONDITIONING: RESULTS IN 118 PATIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2983;
Based on our results we can conclude that age alone should not limit allo-SCT eligibility of patients with hematological malignancies, above all in early disease status. The use in the majority of our patients of treosulfan, an alkylating agent with a low toxic profile, could have contributed to the low incidence of NRM without negatively affecting long-term disease control.
- Ovastat (treosulfan) / Medac, sirolimus / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS ≥ 65 YEARS WITH HEMATOLOGICAL MALIGNANCIES AFTER MYELOABLATIVE TREOSULFAN-BASED CONDITIONING: RESULTS IN 118 PATIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2982;
Based on our results we can conclude that age alone should not limit allo-SCT eligibility of patients with hematological malignancies, above all in early disease status. The use in the majority of our patients of treosulfan, an alkylating agent with a low toxic profile, could have contributed to the low incidence of NRM without negatively affecting long-term disease control.
- Ovastat (treosulfan) / Medac, sirolimus / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS ≥ 65 YEARS WITH HEMATOLOGICAL MALIGNANCIES AFTER MYELOABLATIVE TREOSULFAN-BASED CONDITIONING: RESULTS IN 118 PATIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2981;
Based on our results we can conclude that age alone should not limit allo-SCT eligibility of patients with hematological malignancies, above all in early disease status. The use in the majority of our patients of treosulfan, an alkylating agent with a low toxic profile, could have contributed to the low incidence of NRM without negatively affecting long-term disease control.
- Leustatin (cladribine) / J&J
[VIRTUAL] ALLOGENIC STEM CELL TRANSPLANTATION IN ADVANCED SYSTEMIC MASTOCYTOSIS AFTER CYTOREDUCTIVE TREATMENT WITH CLADRIBINE - A SINGLE CENTER EXPERIENCE ON TWO PATIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2929;
Our experience shows feasibility and short-term efficacy of ASCT in ASM-AHN after induction of best possible remission with several cycles of cladribine and treosulfan-based conditioning. Mediator release may remain an important issue during and after transplantation and its differentiation from GvHD may be difficult.
- Leustatin (cladribine) / J&J
[VIRTUAL] ALLOGENIC STEM CELL TRANSPLANTATION IN ADVANCED SYSTEMIC MASTOCYTOSIS AFTER CYTOREDUCTIVE TREATMENT WITH CLADRIBINE - A SINGLE CENTER EXPERIENCE ON TWO PATIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2928;
Our experience shows feasibility and short-term efficacy of ASCT in ASM-AHN after induction of best possible remission with several cycles of cladribine and treosulfan-based conditioning. Mediator release may remain an important issue during and after transplantation and its differentiation from GvHD may be difficult.
- Leustatin (cladribine) / J&J
[VIRTUAL] ALLOGENIC STEM CELL TRANSPLANTATION IN ADVANCED SYSTEMIC MASTOCYTOSIS AFTER CYTOREDUCTIVE TREATMENT WITH CLADRIBINE - A SINGLE CENTER EXPERIENCE ON TWO PATIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2927;
Our experience shows feasibility and short-term efficacy of ASCT in ASM-AHN after induction of best possible remission with several cycles of cladribine and treosulfan-based conditioning. Mediator release may remain an important issue during and after transplantation and its differentiation from GvHD may be difficult.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] CASE REPORT: CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION (CAEBV) CONTROLLED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT) AND TRANSFUSION OF EBV-SPECIFIC T-CELLS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2903;
Treatment with EBV-specific T-cells from a third party donor followed by alloHSCT from an EBV seropositive donor is an effective therapeutic approach in CAEBV. As EBV-viremia was cleared after the administration of ATG in the alloHSCT setting for the first time in the patient, ATG might be further analysed as a potential treatment option in T-cell-type CAEBV due to its depletive activity on T-cells.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] CASE REPORT: CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION (CAEBV) CONTROLLED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT) AND TRANSFUSION OF EBV-SPECIFIC T-CELLS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2902;
Treatment with EBV-specific T-cells from a third party donor followed by alloHSCT from an EBV seropositive donor is an effective therapeutic approach in CAEBV. As EBV-viremia was cleared after the administration of ATG in the alloHSCT setting for the first time in the patient, ATG might be further analysed as a potential treatment option in T-cell-type CAEBV due to its depletive activity on T-cells.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] CASE REPORT: CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION (CAEBV) CONTROLLED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHSCT) AND TRANSFUSION OF EBV-SPECIFIC T-CELLS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2901;
Treatment with EBV-specific T-cells from a third party donor followed by alloHSCT from an EBV seropositive donor is an effective therapeutic approach in CAEBV. As EBV-viremia was cleared after the administration of ATG in the alloHSCT setting for the first time in the patient, ATG might be further analysed as a potential treatment option in T-cell-type CAEBV due to its depletive activity on T-cells.
- cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] FLAT REGIMEN AS MYELOABLATIVE CONDITIONING WITH LIMITED TOXICITIES FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS IN 30 PATIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2567;
consolidation of AML in CR1 with the new myeloablative FLAT regimen and ASCT was feasibile and well tolerated, even in patients above 65 years of age. Around 50% of pts, regardless of age, mostly with favourable or intermediate genetic risk, obtained prolonged survival without relapse.
- cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] FLAT REGIMEN AS MYELOABLATIVE CONDITIONING WITH LIMITED TOXICITIES FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS IN 30 PATIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2566;
consolidation of AML in CR1 with the new myeloablative FLAT regimen and ASCT was feasibile and well tolerated, even in patients above 65 years of age. Around 50% of pts, regardless of age, mostly with favourable or intermediate genetic risk, obtained prolonged survival without relapse.
- cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] FLAT REGIMEN AS MYELOABLATIVE CONDITIONING WITH LIMITED TOXICITIES FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS IN 30 PATIENTS (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2565;
consolidation of AML in CR1 with the new myeloablative FLAT regimen and ASCT was feasibile and well tolerated, even in patients above 65 years of age. Around 50% of pts, regardless of age, mostly with favourable or intermediate genetic risk, obtained prolonged survival without relapse.
- Ovastat (treosulfan) / Medac, melphalan / Generic mfg.
[VIRTUAL] IMMEDIATE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NPM1-MUTATED AML IN MOLECULAR RELAPSE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2564;
In pts with hematological relapse at the time of HSCT Melphalan (Mel, 100mg/m2) before Treo/Flu was added to induce aplasia... Although the number of pts is small and the follow-up short, this analysis shows the efficacy and feasibility of early allogeneic HSCT in molecular relapse for NPM positive AML pts and should be confirmed in a greater number of pts.
- Ovastat (treosulfan) / Medac, melphalan / Generic mfg.
[VIRTUAL] IMMEDIATE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NPM1-MUTATED AML IN MOLECULAR RELAPSE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2563;
In pts with hematological relapse at the time of HSCT Melphalan (Mel, 100mg/m2) before Treo/Flu was added to induce aplasia... Although the number of pts is small and the follow-up short, this analysis shows the efficacy and feasibility of early allogeneic HSCT in molecular relapse for NPM positive AML pts and should be confirmed in a greater number of pts.
- Ovastat (treosulfan) / Medac, melphalan / Generic mfg.
[VIRTUAL] IMMEDIATE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NPM1-MUTATED AML IN MOLECULAR RELAPSE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2562;
In pts with hematological relapse at the time of HSCT Melphalan (Mel, 100mg/m2) before Treo/Flu was added to induce aplasia... Although the number of pts is small and the follow-up short, this analysis shows the efficacy and feasibility of early allogeneic HSCT in molecular relapse for NPM positive AML pts and should be confirmed in a greater number of pts.
- Ovastat (treosulfan) / Medac, melphalan / Generic mfg., busulfan / Generic mfg.
[VIRTUAL] PULMONARY COMPLICATIONS (PC) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN CHILDREN WITH HIGH-RISK ACUTE LEUKEMIA (AL) (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2540;
Intensity of conditioning regimen does not affect the incidence of PC in patients with CR. The use of RICs in relapse increases incidence of PC.